Q3 sales broadly in line, 2025 and 2027 targets reiterated
21/10/25 -"Eurofins Scientific’s Q3 results were broadly in line with our expectations and Visible Alpha consensus. The organic growth was slightly below expectations, with BioPharma slowing down ..."
Pages
47
Language
English
Published on
21/10/25
You may also be interested by these reports :
21/10/25
Eurofins Scientific’s Q3 results were broadly in line with our expectations and Visible Alpha consensus. The organic growth was slightly below ...
07/10/25
FICO’s launch of the Mortgage Direct Licence Programme – which allows resellers to obtain scores directly from them, thereby bypassing credit ...
23/09/25
After a decent close to 2024 (i.e. March-end FY25), management guidance for 2025 seemed overambitious, given the macro environment, especially ...
04/09/25
The change in the target price reflects the update of our estimates and the effect on DCF and peer-based valuations. Despite a challenging macro ...